In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase II study to assess survival with HAIC or HAIC converted to sorafenib. | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma HICS 55 An open label non-comparative phase II trial